Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease (original) (raw)
An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
luisa Arna
CNS & Neurological Disorders - Drug Targets, 2011
View PDFchevron_right
New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists
Jadwiga Wardas
Life Sciences, 2005
View PDFchevron_right
Targeting adenosine A 2A receptors in Parkinson's disease
Kjell Fuxe
Trends in Neurosciences, 2006
View PDFchevron_right
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease
Mojgan Aghazadeh Tabrizi, Nicola Simola
Journal of The Neurological Sciences, 2006
View PDFchevron_right
Adenosine A 2A receptors, dopamine D 2 receptors and their interactions in Parkinson's disease
Kjell Fuxe
Movement Disorders, 2007
View PDFchevron_right
Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease
Jadwiga Wardas
Neurotoxicity Research, 2001
View PDFchevron_right
Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches
Luiza Nazario
Frontiers in neuroscience, 2017
View PDFchevron_right
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications
Jadwiga Wardas
Progress in Neurobiology, 2007
View PDFchevron_right
Adenosine A2Areceptor antagonist treatment of Parkinson’s disease
Francesco Bibbiani
Neurology, 2003
View PDFchevron_right
Adenosine A2A-Receptor Antagonism and Pathophysiology of Parkinson’s Disease and Drug-Induced Movement Disorders
Jaime Kulisevsky
European Neurology, 2012
View PDFchevron_right
Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease
Roberto Rimondini
Parkinsonism & Related Disorders, 2001
View PDFchevron_right
Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Christa Mueller
Recent Patents on CNS Drug Discovery, 2007
View PDFchevron_right
Adenosine A 2A Receptor Antagonists: New 8-Substituted 9-Ethyladenines as Tools for in vivo Rat Models of Parkinson's Disease
Catia Lambertucci
ChemMedChem, 2009
View PDFchevron_right
Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys
Ronald Pearce
Annals of Neurology, 1998
View PDFchevron_right
Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats
Rafael Lujan
Disease Models & Mechanisms, 2014
View PDFchevron_right
Receptor heteromerization in adenosine A2A receptor signaling Relevance for striatal function and Parkinson's disease
Rafael Franco
View PDFchevron_right
Untangling dopamine-adenosine receptor assembly in experimental parkinsonism
Francisco Ciruela
Disease Models & Mechanisms, 2014
View PDFchevron_right
ST 1535: a preferential A2A adenosine receptor antagonist
maria assunta di cesare
The International Journal of Neuropsychopharmacology, 2005
View PDFchevron_right
Dopamine D2 receptor-mediated modulation of adenosine A2A receptor agonist binding within the A2AR/D2R oligomer framework
Martha Soler
Neurochemistry International, 2013
View PDFchevron_right
Adenosine Receptors as a Paradigm to Identify Dimer/Oligomers of G-Protein-Coupled Receptors and as Targets in Parkinson’s Disease and Schizophrenia
Gemma Navarro
Springer eBooks, 2018
View PDFchevron_right
Functional impact of the G279S substitution in the adenosine A1-receptor (A1R-G279S), a mutation associated with Parkinson's disease
Michael Freissmuth
Molecular Pharmacology, 2020
View PDFchevron_right
Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum
Michele Zoli
Neuroreport, 2001
View PDFchevron_right
A Double-Blind Crossover, Placebo-Controlled Study of the Adenosine A2A Antagonist Theophylline in Parkinson's Disease
Miquel Casas
Clinical Neuropharmacology, 2002
View PDFchevron_right
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease
Imtiaz Ahmed
Neurology, 2011
View PDFchevron_right
A new D2 dopamine receptor agonist allosterically modulates A2A adenosine receptor signalling by interacting with the A2A/D2 receptor heteromer
Elisa Nuti
Cellular Signalling, 2012
View PDFchevron_right
Discovery of nonxanthine adenosine A 2A receptor antagonists for the treatment of Parkinson's disease
Colin T Dourish
Neurology, 2003
View PDFchevron_right
Distribution, biochemistry and function of striatal adenosine A2A receptors
G. Fisone
Progress in neurobiology, 1999
View PDFchevron_right